Resection of primary lesion for patients with metastatic breast cancer: where are we now?

被引:6
|
作者
Hu, Qiancheng [1 ]
Zhong, Xiaorong [1 ,2 ,3 ]
Liu, Xu [2 ]
Xie, Yuxin [1 ,2 ]
Hu, Kejia [2 ]
He, Ping [1 ,3 ]
Lu, Donghao [1 ,3 ,4 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Med Sch, West China Hosp, Dept Med Oncol,Canc Ctr, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Med Sch, West China Hosp,Natl Collaborat Innovat Ctr Bioth, State Key Lab Biotherapy,Lab Tumor Mol Diag, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Chengdu 610041, Sichuan, Peoples R China
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
基金
中国国家自然科学基金;
关键词
Breast cancer; distant metastasis; resection of the primary lesion;
D O I
10.21037/cco.2018.05.03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is largely unclear that whether or not surgical resection of the primary tumors could confer survival benefit among patients with metastatic breast cancer at initial presentation. We thoroughly reviewed the up-to-date evidence on surgical resection of the primary lesion in metastatic breast cancer, including comparative studies (of particular interest in risk modifiers, the type, and timing of surgical procedures), Chinese and international guidelines, as well as the progress of clinical trials. Partial modified radical mastectomy and breast-conserving surgery are by far the most common choices for patients with metastatic breast cancer. Patients with certain characteristics, for example, younger than 45 years of age or with oligometastasis, might benefit from the surgery. The type and timing of surgical procedures are still in debate according to the guidelines from different countries. Forthcoming evidence from the ongoing clinical trials might help close the knowledge gaps in surgical treatment for patients with metastatic breast cancer and aid the decision-making in clinical practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
    Mazzitelli, Carlotta
    Santini, Donatella
    Corradini, Angelo Gianluca
    Zamagni, Claudio
    Trere, Davide
    Montanaro, Lorenzo
    Taffurelli, Mario
    DIAGNOSTICS, 2023, 13 (07)
  • [2] Metformin and Breast Cancer: Where Are We Now?
    Cejuela, Monica
    Martin-Castillo, Begona
    Menendez, Javier A.
    Pernas, Sonia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (05)
  • [3] Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?
    Fedele, Palma
    Calvani, Nicola
    Marino, Antonella
    Orlando, Laura
    Schiavone, Paola
    Quaranta, Annamaria
    Cinieri, Saverio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 (02) : 243 - 251
  • [4] Ethnicity and breast cancer in the UK: Where are we now?
    Gathani, Toral
    Chaudhry, Anushka
    Chagla, Leena
    Chopra, Sharat
    Copson, Ellen
    Purushotham, Arnie
    Vidya, Raghavan
    Cutress, Ramsey
    EJSO, 2021, 47 (12): : 2978 - 2981
  • [5] Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
    Omarini, Claudia
    Guaitoli, Giorgia
    Pipitone, Stefania
    Moscetti, Luca
    Cortesi, Laura
    Cascinu, Stefano
    Piacentini, Federico
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 91 - 103
  • [6] Targeted therapies in breast cancer: Where are we now?
    Di Cosimo, Serena
    Baselga, Jose
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2781 - 2790
  • [7] Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?
    Villasco, Andrea
    D'Alonzo, Marta
    BREAST JOURNAL, 2020, 26 (10): : 2018 - 2020
  • [8] Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review
    Kent, Collin L.
    McDuff, Susan G. R.
    Salama, Joseph K.
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (05) : 5954 - 5968
  • [9] Combined primary site resection and metastasectomy in patients with metastatic breast cancer
    Bilani, Nadeem
    Elson, Leah
    Liang, Hong
    Elimimian, Elizabeth
    Nahleh, Zeina
    CANCER RESEARCH, 2021, 81 (04)
  • [10] miRNA - Therapeutic tool in breast cancer? Where are we now?
    Zaleska, Karolina
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2015, 20 (02) : 79 - 86